PL422220A1 - Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania - Google Patents

Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Info

Publication number
PL422220A1
PL422220A1 PL422220A PL42222017A PL422220A1 PL 422220 A1 PL422220 A1 PL 422220A1 PL 422220 A PL422220 A PL 422220A PL 42222017 A PL42222017 A PL 42222017A PL 422220 A1 PL422220 A1 PL 422220A1
Authority
PL
Poland
Prior art keywords
syrup
obtaining
pharmaceutical composition
zinc gluconate
favourably
Prior art date
Application number
PL422220A
Other languages
English (en)
Other versions
PL239019B1 (pl
Inventor
Hanna WAHL
Marek DĄBROWA
Anna OSTROWSKA
Małgorzata Kowalska-Parteka
Jarosław PASIŃSKI
Arkadiusz MADEJCZYK
Original Assignee
Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia filed Critical Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority to PL422220A priority Critical patent/PL239019B1/pl
Priority to AU2018301189A priority patent/AU2018301189A1/en
Priority to PCT/PL2018/050029 priority patent/WO2019013658A1/en
Priority to UAA202000918A priority patent/UA127658C2/uk
Priority to EP18831595.6A priority patent/EP3651803A4/en
Priority to US16/631,026 priority patent/US11135162B2/en
Priority to RU2020106791A priority patent/RU2778647C2/ru
Publication of PL422220A1 publication Critical patent/PL422220A1/pl
Publication of PL239019B1 publication Critical patent/PL239019B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonian cynku, charakteryzująca się tym, że zawiera substancję słodzącą wybraną z grupy disacharydów, korzystnie sacharozę lub/i z grupy polioli, korzystnie maltitol, substancję ułatwiającą rozpuszczanie z grupy alkoholi wodorotlenowych lub ich mieszanin, korzystnie glikol propylenowy, glicerol, substancje konserwujące wybrane z grupy estrów kwasu parahydroksybenzoesowego i ich mieszanin, korzystnie metyluparahydroksybenzoesan, propylu parahydroksybenzoesanu, słodzik, korzystnie sacharynę sodową lub sukralozę oraz substancje ustalające pH roztworu w zakresie od 5,7 do 12,0 korzystnie aromat oraz jej sposób otrzymywania. Zgłoszenie, ponadto, dotyczy sposobu otrzymywania przedmiotowej kompozycji.
PL422220A 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania PL239019B1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL422220A PL239019B1 (pl) 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania
AU2018301189A AU2018301189A1 (en) 2017-07-14 2018-06-21 A pharmaceutical composition in the form of an aqueous solution, preferably a syrup, containing inosine pranobex and zinc gluconate and a method of preparation thereof
PCT/PL2018/050029 WO2019013658A1 (en) 2017-07-14 2018-06-21 PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS SOLUTION, PREFERABLY SYRUP, CONTAINING PRANOBEX INOSINE AND ZINC GLUCONATE AND PREPARATION METHOD THEREOF
UAA202000918A UA127658C2 (uk) 2017-07-14 2018-06-21 Фармацевтична композиція у вигляді водного розчину, переважно сиропу, що містить інозин пранобекс і глюконат цинку, і спосіб її отримання
EP18831595.6A EP3651803A4 (en) 2017-07-14 2018-06-21 PHARMACEUTICAL COMPOSITION IN THE FORM OF AN AQUEOUS SOLUTION, PREFERABLY A SYRUP, CONTAINING INOSINE PRANOBEX AND ZINC GLUCONATE AND PROCESS FOR PREPARATION
US16/631,026 US11135162B2 (en) 2017-07-14 2018-06-21 Pharmaceutical composition in the form of an aqueous solution, 1A syrup, containing inosine pranobex and zinc gluconate and a method of preparation thereof
RU2020106791A RU2778647C2 (ru) 2017-07-14 2018-06-21 Фармацевтическая композиция в виде водного раствора, предпочтительно сиропа, содержащая инозина пранобекс и глюконат цинка, и способ ее получения

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422220A PL239019B1 (pl) 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Publications (2)

Publication Number Publication Date
PL422220A1 true PL422220A1 (pl) 2019-01-28
PL239019B1 PL239019B1 (pl) 2021-10-25

Family

ID=65002643

Family Applications (1)

Application Number Title Priority Date Filing Date
PL422220A PL239019B1 (pl) 2017-07-14 2017-07-14 Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania

Country Status (6)

Country Link
US (1) US11135162B2 (pl)
EP (1) EP3651803A4 (pl)
AU (1) AU2018301189A1 (pl)
PL (1) PL239019B1 (pl)
UA (1) UA127658C2 (pl)
WO (1) WO2019013658A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL238168B1 (pl) * 2019-02-04 2021-07-12 Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia Stała postać dawkowania zawierająca glukonian cynku oraz pranobeks inozyny, jej sposób otrzymywania oraz zastosowanie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131618A (ja) * 2004-10-04 2006-05-25 Taisho Pharmaceut Co Ltd 亜鉛化合物配合組成物
WO2006138518A1 (en) * 2005-06-17 2006-12-28 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
UA32464U (uk) * 2008-02-20 2008-05-12 Univ Oo Bohomolets Nat Medical Спосіб комплексного лікування дітей, хворих на хронічну форму епштейна-барр вірусної інфекції
WO2012096655A1 (en) * 2011-01-11 2012-07-19 Sam Poon Ang Compositions for treating chronic viral infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US20060121093A1 (en) * 1999-04-06 2006-06-08 Ream Ronald L Tableted products including active agent
PT1824493E (pt) * 2004-12-06 2008-11-18 Janssen Pharmaceutica Nv Suspensão oral que compreende meloxicam
WO2008092006A2 (en) * 2007-01-24 2008-07-31 Cernofina, Llc Antimicrobial compositions
US8362083B2 (en) * 2008-01-15 2013-01-29 C.B. Fleet Company Inc. Taste-masked docusate compositions
US20120082720A1 (en) * 2010-10-05 2012-04-05 Sam Poon Ang Compositions For Treating Chronic Viral Infections
WO2012103040A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Paraben compositions
CA2858372A1 (en) * 2011-11-10 2013-05-16 Lankenau Institute For Medical Research Compositions and methods for the prevention of microbial infections
RU2557962C1 (ru) * 2014-07-03 2015-07-27 Искандар Халиуллович Исмагилов Фармацевтическая композиция на основе метизопринола для перорального введения
EA201791191A1 (ru) * 2014-12-25 2017-12-29 Сановел Иладж Санайи Ве Тиджарет А.С. Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095266A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения (варианты)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131618A (ja) * 2004-10-04 2006-05-25 Taisho Pharmaceut Co Ltd 亜鉛化合物配合組成物
WO2006138518A1 (en) * 2005-06-17 2006-12-28 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
UA32464U (uk) * 2008-02-20 2008-05-12 Univ Oo Bohomolets Nat Medical Спосіб комплексного лікування дітей, хворих на хронічну форму епштейна-барр вірусної інфекції
WO2012096655A1 (en) * 2011-01-11 2012-07-19 Sam Poon Ang Compositions for treating chronic viral infections

Also Published As

Publication number Publication date
EP3651803A4 (en) 2021-03-24
RU2020106791A (ru) 2021-08-16
US11135162B2 (en) 2021-10-05
WO2019013658A1 (en) 2019-01-17
UA127658C2 (uk) 2023-11-22
AU2018301189A1 (en) 2020-02-13
PL239019B1 (pl) 2021-10-25
RU2020106791A3 (pl) 2021-09-29
US20200138709A1 (en) 2020-05-07
EP3651803A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
HRP20171270T1 (hr) Liofilizirani spoj
HRP20191011T1 (hr) Pripravak za liječenje akni
ATE545341T1 (de) Gelierungszusammensetzungen und -verfahren
EP4011354A1 (en) New cosmetics solvents based on two different components
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
RS53689B1 (en) LIQUID FORMULATION OF DEFERIPRON WITH FAVORABLE TASTE
ZA202100339B (en) Sweetening compositions
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
PL422220A1 (pl) Kompozycja farmaceutyczna w postaci wodnego roztworu, korzystnie syropu, zawierająca pranobeks inozyny oraz glukonianu cynku oraz jej sposób otrzymywania
MX2014000195A (es) Enmascaramiento del amargor.
KR101837446B1 (ko) 알파-망고스틴, 베타-망고스틴, 감마-망고스틴 또는 가르탄닌 화합물을 유효성분으로 함유하는 피부 주름 개선 또는 피부 보습용 조성물
EP4011353A1 (en) New cosmetics solvents comprising ascorbic acid
ES2728452T3 (es) Suplemento alimenticio para mejorar la salud del tejido conectivo
JP6755185B2 (ja) アドヘレンスジャンクション機能強化剤
JP7333751B2 (ja) ヒト抗菌ペプチド産生促進剤
AR097148A1 (es) Composición alimenticia para rumiantes y método para prepararla
ES2749645T3 (es) Loción contra la caída del cabello
WO2024065763A1 (en) Composition for caring for keratin materials
KR102309956B1 (ko) 카모마일 꽃 분말을 포함하는 피부 혈행 개선용 조성물
PL419047A1 (pl) Kompozycja zawierająca furazydynę i sposób jej wytwarzania
UA112541C2 (uk) Застосування гідрохлориду амброксолу для лікування гострого фарингіту
ZA202100338B (en) Sweetening compositions
PL427661A1 (pl) Kompozycja emulsji kosmetycznej w postaci mleczka do oczyszczania skóry, zwłaszcza atopowej
HRP20210717T1 (hr) Spoj koji stimulira kolagen i elastin i topikalni sastavi koji sadrže takav spoj
JP2013177471A (ja) ミノキシジル含有製剤